Microbot Medical (MBOT) Stock Price, News & Analysis

Company Overview

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

Key Stats

• Today's Range: $2.72 to $2.90
• 50-Day Range: $1.39 to $2.83
• 52-Week Range: $0.82 to $3.38
• Volume: 1.24 million shs
• Average Volume: 2.29 million shs
• Market Capitalization: $100.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Microbot Medical Stock Analysis - MarketRank™

Microbot Medical scored higher than 42% of companies evaluated by MarketBeat, and ranked 681st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Microbot Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Microbot Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Microbot Medical are expected to grow in the coming year, from ($0.71) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Microbot Medical is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Microbot Medical is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Microbot Medical has a P/B Ratio of 7.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.45% of the float of Microbot Medical has been sold short.

Short Interest Ratio / Days to Cover

Microbot Medical has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Microbot Medical has recently increased by 5.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Microbot Medical does not currently pay a dividend.

Dividend Growth

Microbot Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

26.45% of the float of Microbot Medical has been sold short.

Short Interest Ratio / Days to Cover

Microbot Medical has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Microbot Medical has recently increased by 5.77%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.45

News Sentiment

Microbot Medical has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Microbot Medical this week, compared to 1 article on an average week.

Search Interest

7 people have searched for MBOT on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Microbot Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Microbot Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.74% of the stock of Microbot Medical is held by insiders.

Percentage Held by Institutions

Only 16.30% of the stock of Microbot Medical is held by institutions.

MBOT Stock Analysis - Frequently Asked Questions

How have MBOT shares performed this year?

Microbot Medical's stock was trading at $1.12 at the beginning of 2025. Since then, MBOT shares have increased by 146.9% and is now trading at $2.7650.
View the best growth stocks for 2025 here.

How were Microbot Medical's earnings last quarter?

Microbot Medical Inc. (NASDAQ:MBOT) posted its quarterly earnings data on Wednesday, May, 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.07.

When did Microbot Medical's stock split?

Microbot Medical shares reverse split on Monday, May 9th 2016. The 1-12 reverse split was announced on Friday, May 6th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 6th 2016. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Microbot Medical's major shareholders?

Microbot Medical's top institutional investors include Goldman Sachs Group Inc. (0.11%) and Virtu Financial LLC (0.08%).
View institutional ownership trends.

How do I buy shares of Microbot Medical?

Shares of MBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Microbot Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Microbot Medical investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), TransEnterix (TRXDW), Pfizer (PFE), Plug Power (PLUG) and Novavax (NVAX).

Company Calendar

• Last Earnings: 5/21/2025
• Today: 5/29/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:MBOT
• CIK: 883975
• Web: www.microbotmedical.com
• Phone: (781) 875-3605
• Fax: 781-556-5347
• Employees: 20
• Year Founded: 2010

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +218.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.74 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -218.30%
• Return on Assets: -158.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.64
• Quick Ratio: 3.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.38 per share
• Price / Book: 7.45

Miscellaneous

• Outstanding Shares: 36,378,000
• Free Float: 25,637,000
• Market Cap: $102.95 million
• Optionable: Optionable
• Beta: 1.15